• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Aug 7, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 6, 2020
    Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020--
  • Jul 27, 2020
    Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020
  • Jul 24, 2020
    Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
    - If Approved, ARIKAYCE Will Be First and Only Therapy in the European Union for This Difficult-to-Treat Condition -
  • Jul 7, 2020
    New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease
    --First update to treatment guidelines in more than a decade, marking important milestone in patient care--
  • Jul 6, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jun 24, 2020
    Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
    --Brensocatib Shown to Reduce Time to First Pulmonary Exacerbation and Reduce Rate of Exacerbations Versus Placebo--
  • Jun 8, 2020
    Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
    --Full Results from Phase 2 WILLOW Study of Brensocatib in NCFBE to be Presented at Virtual ATS Session on June 24, 2020--
  • Jun 5, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 26, 2020
    Insmed to Present at Two June Conferences
Show 5102550100 per page
  • «
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 65
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy